← Leaderboards
Charles L McGarvey
Clinical Center
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Clinical Center
Same institution · by research overlap
Others in their field
Top investigators on “Neoplasm /Cancer Therapy”
- Charles A Coltman · Southwest Oncology Group$171,715,324
- Gregory H Reaman · National Childhood Cancer Foundation$143,691,240
- Norman Wolmark · Nsabp Foundation, Inc.$130,339,857
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Bruce J Hillman · American College Of Radiology$89,322,170
- Philip J Disaia · University Of California Irvine$47,533,330
Research focus
Neoplasm /Cancer TherapyBreast Neoplasm /Cancer DiagnosisFunctional AbilityHuman SubjectHuman MorbidityNeoplasm /Cancer EpidemiologyWomen'S HealthLongitudinal Human StudyNeoplasm /Cancer SurgeryOutcomes ResearchPainPathologic ProcessPatient Oriented ResearchQuality Of LifeQuestionnairesFemaleTherapy Adverse EffectFatigueBody MovementLymphedemaLimb MovementDisease /Disorder Proneness /RiskClinical ResearchCancer Rehabilitation /Care
Grant awards (10)
Morbidity Following Breast Cancer Treatment:a Prospectiv$0
Z01 · FY2006 · CL · contact PI
Morbidity Following The Diagnosis And Treatment Of Patie$0
Z01 · FY2006 · CL · contact PI
Morbidity Following The Diagnosis And Treatment Of Patie$0
Z01 · FY2005 · CL
Morbidity Following Breast Cancer Treatment: Prospective$0
Z01 · FY2005 · CL
Morbidity Following Breast Cancer Treatment: Prospective$0
Z01 · FY2004 · CL
Morbidity Following The Diagnosis &Treatment Of Patient$0
Z01 · FY2004 · CL
Morbidity Following Breast Cancer Treatment:a Prospectiv$0
Z01 · FY2003 · CL
Morbidity Following The Diagnosis And Treatment Of Patie$0
Z01 · FY2003 · CL
Morbidity Following The Diagnosis And Treatment Of Patie$0
Z01 · FY2002 · CL
Morbidity Following Breast Cancer Treatment: Prospective$0
Z01 · FY2002 · CL